LexaGene Completes First Stage of U.S. ARMY DEVCOM Agreement

BEVERLY, Mass., Oct. 29, 2021 (GLOBE NEWSWIRE) -- LexaGene Holdings, Inc., ( OTCQB: LXXGF; TSX-V: LXG ) (“LexaGene” or the “Company”), a molecular diagnostics company that has commercialized an instrument

Related Keywords

Maryland , United States , Gail Winslow , Manoj Nair , Lexagene Miqlab , Jack Regan , Development Agreement , Applications Assay Development At Lexagene , Lexagene Holdings Inc , Chemical Biological Center At Aberdeen Proving Grounds , Venture Exchange Inc , Us Army , Capabilities Development Command , Venture Exchange , Regulation Services Provider , Gene Holdings , Cooperative Research , Combat Capabilities Development Command , Biological Center , Aberdeen Proving Grounds , United States Postal , Director Applications , Assay Development , Jack Regan Chief Executive Officer , Lexagene Holdings , Media Contact , Gail Winslow Director , Corporate Marketing , Sharon Choe Vice President Lavoiehealthscience , Money , Ational ,